New management appointments at Xanodyne
This article was originally published in Scrip
Executive Summary
Xanodyne Pharmaceuticals (US), a speciality company focused on women's healthcare and pain management, has appointed three new members to its executive management team: Natasha Giordano as chief commercial officer; Rita O'Connor as chief financial and information officer; and Peter Wentworth as senior vice-president of human resources. Ms Giordano was most recently president, Americas, at Cegedim Dendrite, while Ms O'Connor was vice-president of finance at NPS Pharmaceuticals and Mr Wentworth was executive vice-president of human resources at Adams Respiratory Therapeutics.
You may also be interested in...
Morgan Lewis expands FDA & healthcare practice
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma appoints new member to board
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
Optimer expands management team
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.